OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $28.00

OrthoPediatrics (NASDAQ:KIDS) had its price objective increased by Truist Financial from $22.00 to $28.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a hold rating on the stock.

Several other research firms have also issued reports on KIDS. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. BTIG Research boosted their target price on OrthoPediatrics from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday. Lake Street Capital increased their price target on OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday. Canaccord Genuity Group raised their price target on OrthoPediatrics from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Stifel Nicolaus increased their price target on OrthoPediatrics from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, OrthoPediatrics presently has an average rating of “Moderate Buy” and a consensus target price of $30.75.

OrthoPediatrics Stock Down 2.1%

KIDS stock opened at $30.87 on Wednesday. OrthoPediatrics has a one year low of $14.42 and a one year high of $32.62. The company’s 50 day moving average price is $23.32 and its two-hundred day moving average price is $19.59. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.55 and a quick ratio of 2.17.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, October 27th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. The business had revenue of $72.66 million during the quarter, compared to analysts’ expectations of $68.50 million. Equities research analysts forecast that OrthoPediatrics will post -1.09 earnings per share for the current year.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, major shareholder Jennifer Pritzker sold 326,700 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the completion of the transaction, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. This represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Pelizzon sold 326,700 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the transaction, the director owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. This trade represents a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 2,100,000 shares of company stock valued at $46,747,931. Corporate insiders own 32.50% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

A number of large investors have recently bought and sold shares of the business. Ellsworth Advisors LLC purchased a new position in OrthoPediatrics in the 3rd quarter valued at about $900,000. GAMMA Investing LLC boosted its holdings in OrthoPediatrics by 70.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock worth $26,000 after buying an additional 481 shares during the last quarter. Squarepoint Ops LLC increased its stake in OrthoPediatrics by 95.0% during the 2nd quarter. Squarepoint Ops LLC now owns 195,468 shares of the company’s stock worth $3,739,000 after buying an additional 95,230 shares in the last quarter. Waverly Advisors LLC increased its stake in OrthoPediatrics by 6.7% during the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock worth $237,000 after buying an additional 775 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter valued at approximately $4,636,002. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.